Over the last decade, impact investment has been on the rise – seeking to combine financial returns with social impact by using the tools of venture capital to make principal investments in private, high-growth companies that have the potential to deliver some measurable social or environmental benefits. The space itself is comparatively new and requires testing of different financing models and appropriate sources of capital to reach its potential and achieve full impact. Patient capital, as one of the capital sources, could enable higher-risk, lower return businesses in the short-run to a point where they can earn sustainable returns over a longer-run so that commercial markets can invest in them.
The session will focus on examining and providing concrete examples on how a series of patient capital support – from grants, to blended finance instruments – can be used to develop the pipeline and ecosystem to build impact investment in the South and Southeast Asian region.
- Why patient capital is different from other kinds of capital on the market and the specific attributes that make it attractive to investee companies.
- The unique challenges of patient capital within South and Southeast Asia, possible solutions to these challenges and tools that can complement such investments to enable maximum impact.
- What opportunities exist for investors to tap into patient capital and what sort of incentives can help bring more transparency and increase activity in the market.
Deputy Chief of Party of USAID Green Invest Asia Pact Global
Deputy Country Director Swisscontact Cambodia
Equity Officer Oikocredit International
Director Insitor Seed SA
Managing Director Impact Investment Exchange (Asia) Pte Ltd